Skip to main navigation

About Us
Products
- MARGENZA^®
Pipeline
Technology
Patients
Investors
Investor Relations
Careers
- Current Openings
- Employee Benefits

Contact Investor Relations

Shareholder Tools

Facebook
LinkedIn
Twitter
RSS

Breadcrumb

Home Investors Contact Investor Relations

Contact Investor Relations

Please submit your question using the form below.

* Indicates required field

Name

Email

Subject

Comments

Leave this field blank

About Us
Our Living Values
Senior Management
Board of Directors
Collaborations
Corporate Compliance & Ethics
Corporate Responsibility
Contact Us

Products
MARGENZA™

Pipeline
Vobra Duo (B7-H3 ADC)
Lorigerlimab (PD-1 × CTLA-4)
Enoblituzumab (anti-B7-H3)
Tebotelimab (PD-1 × LAG-3)
MGC026 (B7-H3 ADC)
MGC028 (ADAM9 ADC)
MGD024 (CD123 × CD3)

Technology
Platforms
Capabilities
Publications

Patients
Clinical Trials
Expanded Access
Resources

Investors

Footer investor menu

Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Investor FAQs
Publications
Contact Us

Careers
Current Openings
Employee Benefits

©2024 MacroGenics, Inc.

Contact Us
Site Map
Privacy Policy
Terms of Use
Other Notices